Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with ALK-positive NSCLC who had not previously received an ALK inhibitor, progression-free survival was significantly longer among patients who received brigatinib than among those who received crizotinib. (Funded by Ariad Pharmaceuticals; ALTA-1L ClinicalTrials.gov number, NCT02737501 .).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Camidge et al. (Tue,) studied this question.

synapsesocial.com/papers/69d76859aa68b335b4f3154e https://doi.org/https://doi.org/10.1056/nejmoa1810171

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials2018 · 144 citations
2Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial2017 · 583 citations
3<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer2008 · 980 citations
4New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,418 citations
5Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial2017 · 9 citations

Bookmark

View Full Paper